Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

Discover a study that demonstrated that baricitinib significantly improved clinical signs of moderate-to-severe paediatric ...

Further, in a mouse model of TEN, oral administration of tofacitinib, or the JAK1 and JAK2 inhibitor baricitinib, reduced STAT1 phosphorylation and disease severity, decreased keratinocyte death ...

When the session moderator asked whether the findings meant cardiovascular risk was no longer a worry with JAK inhibitors ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding the class, though, these treatments all face a complex ...